10x Genomics (TXG)

• Market cap: $1.72B
• 1 day: -4.37%
• 5 days: 4.95%
• 1 month: 20.90%
• 3 months: 67.06%
• 6 months: -5.66%
• Year to date: -1.34%
• 1 year: -31.07%
• 5 years: -85.84%
• 10 years: -73.46%
• Sector: Healthcare
• Industry: Health Information Services

About: 10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives maximum revenue from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).

Employees: 1,306

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

81% more call options, than puts

Call options by funds: $2.66M | Put options by funds: $1.47M

42% more repeat investments, than reductions

Existing positions increased: 105 | Existing positions reduced: 74

7.44% more ownership

Funds ownership: 97.7% [Q4 2024] → 105.14% (+7.44%) [Q1 2025]

9% more first-time investments, than exits

New positions opened: 49 | Existing positions closed: 45

0% more funds holding

Funds holding: 270 [Q4 2024] → 270 (+0) [Q1 2025]

34% less capital invested

Capital invested by funds: $1.5B [Q4 2024] → $993M (-$509M) [Q1 2025]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6.50 54% downside
• Avg. target: $12.56 10% downside
• High target: $18 29% upside

8 analyst ratings

• positive: 4 50%
• neutral: 3 38%
• negative: 1 13%

B of A Securities Derik De Bruin	7% downside $13	Neutral Maintained	26 Jun 2025
Barclays Luke Sergott	7% downside $13	Overweight Maintained	24 Jun 2025
Morgan Stanley Tejas Savant	29% upside $18	Overweight Maintained	19 May 2025
Stephens & Co. Mason Carrico	0% upside $14	Overweight Reiterated	15 May 2025
UBS Dan Leonard	14% downside $12	Neutral Maintained	13 May 2025